Keros Therapeutics, Inc. (KROS)

Keros Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	3.55	0.15	-	20.1	-
Revenue Growth (YoY)	2250.99%	-	-	-	-
Cost of Revenue	18.29	14.08	8.21	55.14	33.86
Gross Profit	-14.74	-13.93	-8.21	-35.04	-33.86
Selling, General & Admin	40.75	34.83	27.53	21.33	12.8
Research & Development	155.34	121.18	79.06	-	-
Operating Expenses	196.09	156.01	106.59	21.33	12.8
Operating Income	-210.83	-169.94	-114.79	-56.37	-46.66
Interest Expense	-	-	-0	-0	-0.01
Interest & Investment Income	23.5	14.76	3.64	0.03	-
Currency Exchange Gain (Loss)	-0.95	-0.21	-0.61	-	-
Other Non Operating Income (Expenses)	1.24	2.4	7.08	-0.38	1.13
Pretax Income	-187.05	-152.99	-104.68	-56.73	-45.53
Income Tax Expense	0.3	-	-	2.01	-0.17
Net Income	-187.35	-152.99	-104.68	-58.74	-45.36
Net Income to Common	-187.35	-152.99	-104.68	-58.74	-45.36
Shares Outstanding (Basic)	37	29	25	23	16
Shares Outstanding (Diluted)	37	29	25	23	16
Shares Change (YoY)	27.13%	16.66%	8.17%	50.48%	566.41%
EPS (Basic)	-5.00	-5.20	-4.15	-2.52	-2.93
EPS (Diluted)	-5.00	-5.20	-4.15	-2.52	-2.93
Free Cash Flow	-162.8	-126.97	-71.3	-63.17	-37.19
Free Cash Flow Per Share	-4.35	-4.31	-2.83	-2.71	-2.40
Gross Margin	-	-	-	-174.34%	-
Operating Margin	-5938.96%	-112543.71%	-	-280.46%	-
Profit Margin	-5277.55%	-101319.21%	-	-292.26%	-
Free Cash Flow Margin	-4585.91%	-84087.42%	-	-314.29%	-
EBITDA	-209.6	-169.13	-114.12	-56	-46.38
EBITDA Margin	-	-	-	-278.58%	-
D&A For EBITDA	1.23	0.82	0.67	0.38	0.28
EBIT	-210.83	-169.94	-114.79	-56.37	-46.66
EBIT Margin	-	-	-	-280.46%	-
Revenue as Reported	3.55	0.15	-	20.1	-

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q